每经记者｜林姿辰 每经编辑｜程鹏 文多 记者|林姿辰 编辑|程鹏 文多 杜恒峰 校对|陈柯名 2月25日，长春高新（SZ000661）以涨停收盘，报97.26元/股，收获2026年开年以来首个涨停；2月26日公司股价继续上涨，盘中一度触及108元，最新股 价报98.5元，总市值为402亿元。截至目前周涨幅超12%。 消息面上，长春高新子公司长春金赛药业有限责任公司（以下简称金赛药业）的GenSci141软膏临床试验申请获批，适应证为用于改善因多种原因导致的 儿童小阴茎。资料显示，这是全球首款针对儿童小阴茎的药物。 图片来源：长春高新公告 《每日经济新闻》记者（以下简称每经记者）注意到，针对儿童小阴茎的文献数量较少，发病率、分类、手术指征、手术年龄等在全球存在争议。这也让 市场对GenSci141软膏的临床进展格外关注。 2月26日，长春高新方面对每经记者表示，这个项目还处于早期阶段，目前没有能对外交流的信息。 小阴茎诊疗面临诸多挑战 一直未有药物获批对应适应证 2023年，为了规范小阴茎的临床管理，尽量减少不当诊疗带来的一系列问题，经中华医学会儿科学分会内分泌遗传代谢学组等组织的专家共同讨论，并参 考国内外的 ...

0.000 .. -4.701 ■ 在 rota to 新浪财经客户端 2 2 1 3 A sina the Sina Finance Mobile Version er 論 193 limily.all(... billathal) 来源：股市直击 2月26日，生物制品板块短线拉升，长春高新触及涨停，三生国健涨超7%，欧林生物、特宝生物、荣昌 生物跟涨。 长春高新受到关注的核心驱动力来自创新药领域的多项关键突破。公司自研的全球首款儿童小阴茎治疗 软膏获批临床，伏欣奇拜单抗作为国内首个IL-1β单抗上市后销售强劲且多地缺货。更重要的是， GenSci098注射液获得13.65亿美元海外BD大单且首付款已到账，为公司带来重大业务增量。公司正从 传统生长激素业务向肿瘤、免疫、内分泌等多管线创新药转型，这些积极进展引发市场广泛关注。 ...

2月25日，上证指数涨0.72%报4147.23点，深证成指涨1.29%报14475.86点，创业板指涨1.41%报3354.82 点。沪深两市成交额2.46万亿元，较前一交易日放量约2604.84亿元。个股涨多跌少，3540只上涨、1529 只下跌、121只持平，题材板块涨幅居前。 今日，A股十大人气热股如下：包钢股份、航天发展、长春高新、云天化、汉缆股份、北方稀土、和邦 生物、金正大、川金诺、利欧股份。 | 热度排名 | 人气个股 | 热度值 | 所属概念 | 热度标签 | | --- | --- | --- | --- | --- | | T | 包钢股份 | 10.0 | 稀土永磁,特钢概念 | 首板涨停 | | 2 | 航天发展 | 9.25 | 军工信息化,商业航天 | 首板涨停 | | 3 | 长春高新 | 8.25 | 生物疫苗,流感 | 首板涨停 | | 4 | 云天化 | 8.0 | 磷化工,化肥 | 2天2板 | | 5 | 汉缆股份 | 7.5 | 柔性直流输电,特高压 | 4天4板 | | 6 | 北方稀土 | 7.5 | 稀土永磁,小金属概念 | 首板涨停 | | 7 | 和邦生物 ...

Core Viewpoint - Changchun High-tech (000661.SZ) is expected to experience a significant decline in operating performance, with a projected net profit attributable to shareholders of 150 million to 220 million yuan for 2025, representing a year-on-year decrease of over 90% [1][4]. Group 1: Financial Performance - In 2024, Changchun High-tech's net profit attributable to shareholders decreased by over 40% year-on-year [2]. - For 2025, the company anticipates a net profit drop of 24.33 billion to 23.63 billion yuan compared to the previous year, with a decline rate of 91.48% to 94.19% [4]. - The company reported a net profit of 1.165 billion yuan for the first three quarters of 2025, down 58.23% year-on-year, with total revenue of 9.807 billion yuan, a decrease of 5.60% [4]. Group 2: Factors Influencing Performance - The decline in net profit is attributed to adjustments in pricing and sales policies for core products, particularly long-acting growth hormones, due to their inclusion in the national medical insurance directory [2][6]. - Increased research and development (R&D) expenses, which reached 2.690 billion yuan in 2024, and higher sales expenses have also impacted profitability [10][12]. - The company is focusing on R&D in traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to tumors, respiratory, and immune systems [10]. Group 3: R&D and Product Development - Changchun High-tech's R&D investment for the first three quarters of 2025 was 1.733 billion yuan, a year-on-year increase of 22.91% [12]. - The company has successfully advanced several products, including the GenSci098 injection project, which received a 70 million USD upfront payment [3][14]. - The R&D expenses have been steadily increasing, with a total of 2.690 billion yuan in 2024, representing 19.97% of total revenue [10]. Group 4: Market Position and Future Outlook - The company has historically relied heavily on growth hormones, which have been referred to as its "cash cow" [6]. - The future ability of Changchun High-tech to reduce its dependence on growth hormones is a key concern for investors [15].

Core Viewpoint - The company, Changchun High-tech (SZ000661), has issued a shocking earnings forecast for 2025, predicting a significant decline in net profit compared to the previous year, primarily due to increased R&D expenses, adjustments in sales strategies following the inclusion of long-acting growth hormone products in the national medical insurance catalog, and losses from its subsidiary [2][3]. Group 1: Earnings Forecast - For 2025, the company expects a net profit attributable to shareholders between 150 million to 220 million yuan, a drastic decrease of 91.48% to 94.19% from 2.583 billion yuan in 2024 [2]. - The forecasted net profit excluding non-recurring items for 2025 is estimated to be between 437 million to 507 million yuan, down 82.09% to 84.56% from 2.830 billion yuan in the previous year [2]. Group 2: Reasons for Profit Decline - The decline in profit is attributed to multiple factors, including increased R&D expenses as several products enter clinical stages and higher sales expenses for promoting new products [3]. - The company adjusted its sales strategies and pricing for long-acting growth hormone products after they were included in the national medical insurance catalog, which negatively impacted revenue and profit [3]. - Losses from the subsidiary, Changchun Baike Biotechnology Co., further contributed to the overall decline in performance [3]. Group 3: Market Position and Challenges - The company holds a 100% market share in the pegylated recombinant human growth hormone injection and a 68.4% market share in short-acting growth hormone products, indicating a strong competitive position [4]. - However, starting in 2024, the company began experiencing a downward trend in performance, with revenues and net profits decreasing by 7.55% and 43.01%, respectively, in 2024 [5]. - The introduction of price reductions for growth hormones in 2025 is expected to exert additional pressure on revenue growth [5]. Group 4: Strategic Initiatives - The company is increasing its R&D investment, which rose by 23% to 1.733 billion yuan in the first three quarters of 2025, representing 17.68% of total revenue [5]. - A recent business development transaction with Yarrow Bioscience, Inc. is expected to yield significant future payments, although these revenues will not be recognized in the 2025 financial statements [6]. - The company is also focusing on expanding its overseas market presence and has submitted an application for listing on the Hong Kong Stock Exchange to support this initiative [6].

Core Viewpoint - Changchun High-tech expects a significant decline in net profit for 2025, projecting between 150 million to 220 million yuan, attributed to increased R&D and sales expenses, as well as strategic adjustments in product delivery to mitigate potential impairment losses [1][2]. Group 1: Financial Performance - The company anticipates a net profit drop for 2025 compared to the previous year, with a forecast of 150 million to 220 million yuan [1]. - Increased R&D expenses and sales costs are impacting short-term profitability, as the company invests in new product development and market promotion [2][3]. - Adjustments in product sales policies and pricing, in response to industry changes and market conditions, have also contributed to reduced revenue and net profit [2]. Group 2: R&D and Product Development - Changchun High-tech is focusing on traditional strengths in endocrine metabolism and women's health, while also exploring innovative directions in oncology, respiratory, and immune-related fields [2]. - The company is actively increasing R&D investments, with several new products entering clinical stages, which is expected to yield long-term benefits despite short-term financial pressures [3]. - The company aims to enhance its R&D efficiency and develop sustainable long-term capabilities by exploring multi-line layouts and systemic solutions in various health sectors [3]. Group 3: Strategic Initiatives - Changchun High-tech is pursuing international expansion and has established a partnership with ALK for specific immunotherapy products, marking a significant step in the Chinese desensitization treatment market [3]. - The company is also planning to list in Hong Kong to strengthen its global strategy and enhance its financing capabilities, aiming to attract international investment for its clinical trials and R&D [4]. - The focus on building an innovative cooperation platform is part of the company's strategy to advance its international presence and drive growth [4].

Core Viewpoint - Changchun Gaoxin has announced a significant decline in its expected net profit for 2025, projecting a decrease of 91.48% to 94.19% year-on-year, primarily due to increased R&D expenses and market challenges in the pharmaceutical industry [1] Group 1: Financial Projections - The company expects a net profit attributable to shareholders of 150 million to 220 million yuan for 2025, representing a year-on-year decrease of 91.48% to 94.19% [1] - The projected net profit after deducting non-recurring gains and losses is estimated to be between 437 million and 507 million yuan, reflecting a year-on-year decline of 82.09% to 84.56% [1] Group 2: Reasons for Profit Decline - Increased R&D expenses due to the company's focus on traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immune diseases [1] - The launch of new products, including the first domestic innovative biological agent for acute gouty arthritis, has led to increased sales and marketing expenses, necessitating a market cultivation period for new products [1] - Adjustments in sales policies and pricing in response to industry policy changes and market conditions have resulted in reduced revenue and net profit [1] - The company’s subsidiary, Changchun Baike Biotechnology Co., is expected to incur losses in 2025, further impacting overall performance [1] Group 3: Licensing Agreement - The company’s subsidiary, Shanghai Saizeng Medical Technology Co., has entered into an exclusive licensing agreement for the GenSci098 injection project, which is expected to yield a total of $1.2 billion in upfront and milestone payments [1] - The agreement includes a non-refundable upfront payment of $70 million and an additional $50 million in milestone payments, with potential for up to $1.365 billion in further milestone payments and over 10% in sales royalties post-product launch [1] - The financial impact of this licensing agreement will not be reflected in the current reporting period due to accounting policy requirements [1]

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [31]. Core Insights - The JPMorgan Healthcare Conference highlighted six top candidate drugs in the Chinese market for 2026, with four originating from local innovative companies, showcasing their R&D capabilities that can compete with multinational brands [4]. - The report anticipates continued active merger and acquisition (M&A) transactions in the biopharmaceutical sector, with a projected global M&A transaction volume reaching $5.1 trillion in 2025, led by a 44% increase in the healthcare sector [4]. - Investment strategies suggest focusing on innovative Chinese pharmaceutical companies that are enhancing their global competitiveness, particularly in therapeutic areas like metabolism, chronic diseases, and central nervous system disorders, as well as potential technology platforms such as small nucleic acid drugs and CAR-T therapies [5]. Summary by Sections Industry Overview - The JPMorgan Healthcare Conference showcased 24 Chinese innovative pharmaceutical companies, including BeiGene and Legend Biotech, presenting their latest R&D and commercialization achievements [4]. - The report emphasizes the importance of the Chinese market, identifying six candidate drugs that are expected to make significant impacts in 2026 [4]. Investment Strategy - The report recommends focusing on innovative therapeutic areas beyond traditional oncology and immunology, such as metabolic disorders and chronic diseases [5]. - It also highlights the potential of emerging technology platforms, suggesting investment in companies that are advancing in areas like peptide drugs and small nucleic acids [5]. Market Performance - The pharmaceutical sector experienced a decline of 0.68% last week, while the Shanghai and Shenzhen 300 Index fell by 0.57%, ranking the pharmaceutical industry 17th among 27 sectors [20]. - In contrast, the Hong Kong pharmaceutical sector saw an increase of 2.38%, outperforming the Hang Seng Index, which rose by 2.56%, ranking 6th among 11 sectors [30].

Core Viewpoint - The company has signed an exclusive licensing agreement for the GenSci098 injection project with Yarrow Bioscience, which includes a $70 million upfront payment to support its cash reserves and future development plans [2][3]. Group 1: Licensing Agreement Details - The exclusive licensing agreement was approved by the company's board on December 15, 2025, allowing Yarrow to develop, produce, and commercialize GenSci098 outside Greater China [3]. - The first payment of $70 million was received by the company on January 14, 2026, which will enhance the company's cash reserves and support its international strategy [3]. Group 2: GenSci098 Injection Project - GenSci098 is a humanized monoclonal antibody designed to treat thyroid-related conditions, specifically targeting TSHR to inhibit thyroid hormone synthesis and release [4]. - Clinical trials for GenSci098 have been approved in both mainland China and the United States for thyroid eye disease (TED) and Graves' disease (GD), indicating its potential as a new treatment option [4].

Core Viewpoint - Changchun High-tech has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project, receiving an initial payment of $70 million, which enhances the company's cash reserves and supports its future R&D and internationalization strategy [1][4]. Group 1: Licensing Agreement Details - The agreement allows Yarrow to have global exclusive rights for the development, production, and commercialization of GenSci098 injection outside Greater China, specifically targeting thyroid-related eye disease (TED) and Graves' disease (GD) [3]. - Changchun High-tech's subsidiary, SaiZeng Medical, retains the rights for development and commercialization of GenSci098 in China [3]. Group 2: Product Information - GenSci098 is a humanized monoclonal antibody designed to treat hyperthyroidism by blocking the synthesis and release of thyroid hormones and preventing the proliferation of thyroid cells [2]. - The injection has shown potential in preclinical data and ongoing Phase I clinical trials for TED, with plans for further clinical development targeting GD [2]. Group 3: Financial Implications - SaiZeng Medical is expected to receive a total of $120 million in upfront and milestone payments, including the initial $70 million and an additional $50 million for recent development milestones [4]. - The agreement also includes potential milestone payments of up to $1.365 billion and over 10% sales royalties post-product launch [4].